IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript Summary
IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript Summary
Operating expenses declined by $1.1 million due to cost reduction initiatives.The following is a summary of the IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript:
以下是艾裏德克斯公司（IRIX）2024年第三季度業績會文本摘要：
Financial Performance:
財務表現：
IRIDEX reported a 10% decline in Q3 revenue year-over-year, totaling $11.6 million.
Gross profit was $4.3 million with a gross margin of 37.3%, down from 43.7%.
Operating expenses declined by $1.1 million due to cost reduction initiatives.
Net loss widened slightly to $1.9 million, or $0.12 per share.
艾裏德克斯報告第三季度營業收入同比下降10%，總計1160萬美元。
毛利潤爲430萬美元，毛利率爲37.3%，較43.7%下降。
由於成本削減舉措，營業費用下降110萬美元。
淨損失略有擴大至190萬美元，每股0.12美元。
Business Progress:
業務進展：
Under new CEO, Patrick Mercer, IRIDEX is focusing on outsourcing manufacturing for competitive pricing and enhancing product offerings with the introduction of the I-5 laser platform.
A cost-cutting program to align expenses with revenues has been initiated to achieve EBITDA breakeven in Q4 2024.
The strategic review process is actively ongoing with multiple parties, expected to result in significant transactions by the year-end.
在新任CEO帕特里克·默瑟的領導下，艾裏德克斯專注於爲獲得競爭價格而外包製造業，並通過引入I-5激光平台來增強產品系列。
已經啓動了一個成本削減計劃，以使支出與營業收入保持一致，以在2024年第四季度實現EBITDA盈虧平衡。
戰略審查過程正在積極進行中，有多方參與，預計將在年底實現重大交易。
Opportunities:
機會：
The revised LCD for glaucoma reimbursement effective November 17 offers new opportunities for IRIDEX's cyclophotocoagulation products, potentially increasing adoption by physicians restricted from using MIGS devices.
從2022年11月17日生效的青光眼報銷修訂單開始，爲艾裏德克斯的視網膜輻照產品提供了新機會，有可能增加醫生的採用，這些醫生因無法使用微創手術設備而受限。
Risks:
風險：
No explicit risks detected.
沒有發現任何明確風險。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。內容準確性無法完全保證。如需更全面詳情，請參閱IR網站。本文僅供投資者參考，不具有任何指導或推薦建議。